BIRC5 Antibody

What is BIRC5/Survivin and where is it expressed in normal and pathological tissues?

BIRC5 (Baculoviral IAP Repeat Containing 5), also known as Survivin, is a member of the inhibitor of apoptosis (IAP) protein family that plays crucial roles in cell division and inhibition of apoptosis. According to literature-based expression profiles, BIRC5 is expressed in multiple tissues including:

• Lung and mammary gland tissues

• Muscle tissue

• Cervix carcinoma cells

• Myeloid leukemia cells

• Mammary cancer cells

• Neuroblastoma cells

BIRC5 expression is generally cytoplasmic, with some studies also reporting nuclear localization in certain cancer types. When evaluating BIRC5 expression, researchers should anticipate variation in expression levels across different tissue types, with typically higher expression in cancerous tissues compared to normal counterparts .

What applications are commonly validated for anti-BIRC5 antibodies in research?

Anti-BIRC5 antibodies can be utilized across multiple experimental platforms, with validation for specific applications depending on the antibody clone and manufacturer. Common applications include:

• Western Blotting (WB) for protein expression quantification

• Immunohistochemistry (IHC) for tissue localization studies

• Flow Cytometry for cellular analysis

• Enzyme-Linked Immunosorbent Assay (ELISA) for detection of circulating antibodies

When selecting an anti-BIRC5 antibody, researchers should verify validation data for their specific application and tissue of interest. For example, the Picoband® anti-Survivin/BIRC5 antibody (RP1052) has been specifically validated for Flow Cytometry, IHC, and WB applications in mouse samples .

What are the recommended storage conditions for maintaining anti-BIRC5 antibody activity?

Proper storage is critical for maintaining antibody performance. For lyophilized anti-BIRC5 antibodies:

• Store at -20°C for up to one year from the date of receipt

• After reconstitution, store at 4°C for up to one month for active use

• For longer storage after reconstitution, aliquot and store at -20°C for up to six months

• Avoid repeated freeze-thaw cycles as they can compromise antibody performance

These storage guidelines are essential for maintaining antibody specificity and sensitivity in experimental applications. Researchers should monitor antibody performance with appropriate positive controls when using antibodies that have been stored for extended periods .

How should researchers interpret unexpected BIRC5 staining patterns in experimental tissues?

When encountering unexpected staining patterns, researchers should consider multiple factors before concluding whether the results represent true biological variation or technical artifacts:

• Validate findings with alternative antibody clones or detection methods

• Compare with literature-reported expression profiles for the specific tissue

• Include appropriate positive and negative controls

• Consider fixation and processing effects on epitope availability

For example, researchers have observed positive staining in lung cytoplasm using anti-BIRC5 antibodies, which aligns with literature showing BIRC5 expression in lung tissue. According to published data (PubMed ID: 15489334), BIRC5 is expressed in lung, mammary gland, and muscle tissues, supporting the validity of such observations .

What methodological considerations are critical when developing ELISA-based detection of anti-BIRC5 autoantibodies in cancer patients?

Development of robust ELISA systems for detecting anti-BIRC5 autoantibodies requires careful optimization of multiple parameters:

• Antigen coating concentration: Optimal coating concentration must be determined empirically (e.g., 0.5 μg/ml for BIRC5 recombinant protein as used in hepatocellular carcinoma studies)

• Serum dilution: Typically 1:100 dilution is used, but this should be validated for specific clinical populations

• Control inclusion: Each plate should include:

  • Empty controls (no antigen)

  • Quality control sera with known consistent values

• Detection method: TMB color rendering technique is commonly employed

• Data normalization: Signal-to-noise ratio (SNR) values may provide better representation of autoantibody levels than raw optical density

These methodological details are essential for developing reproducible assays that can reliably detect anti-BIRC5 autoantibodies in clinical samples, as demonstrated in recent hepatocellular carcinoma biomarker research .

How do circulating anti-BIRC5 autoantibody levels correlate with cancer stage and prognosis?

Research examining anti-BIRC5 autoantibodies as cancer biomarkers has yielded complex results that vary by cancer type and stage. In non-small cell lung cancer (NSCLC) studies:

The data reveals that anti-BIRC5 IgG levels did not significantly differ between NSCLC patients and controls (combined P = 0.904). Furthermore, when stratified by disease stage:

• Early stage NSCLC: No significant changes in anti-BIRC5 IgG levels compared to controls (combined P = 0.947)

• Late stage NSCLC: No significant changes in anti-BIRC5 IgG levels compared to controls (combined P = 0.865)

This contrasts with other tumor-associated antigens like MYC, where antibody levels showed significant elevation in NSCLC patients . These findings emphasize the importance of cancer-type specificity when evaluating autoantibodies as biomarkers.

What strategies can improve the diagnostic utility of anti-BIRC5 autoantibodies in AFP-negative hepatocellular carcinoma?

Recent research has identified anti-BIRC5 autoantibodies as potentially valuable biomarkers for AFP-negative hepatocellular carcinoma (ANHCC). To optimize their diagnostic utility:

• Protein microarray approach: Using focused protein microarrays with multiple cancer-associated antigens (154 proteins derived from 138 cancer-related genes) can identify autoantibody signatures

• Multi-center validation: Validation across independent cohorts is essential:

  • Cohort 1: 57 ANHCC vs. 57 normal controls

  • Cohort 2: 28 ANHCC vs. 28 normal controls

  • Evaluation phase: 95 ANHCC, 149 APHCC, and 244 normal controls

• Sample stratification: Consider confounding factors such as:

  • HBV infection status

  • TNM staging

  • Metastasis status

• Combined biomarker panels: Evaluate anti-BIRC5 autoantibodies alongside other autoantibodies to improve sensitivity and specificity

Using such approaches, researchers have demonstrated elevated occurrence of anti-BIRC5 autoantibodies in ANHCC compared to normal controls, providing a potential complementary biomarker for patients with ANHCC where traditional AFP testing is ineffective .

How can researchers address contradictory results between anti-BIRC5 antibody studies in different cancer types?

When faced with contradictory results in anti-BIRC5 antibody studies across cancer types, researchers should systematically investigate several factors:

• Antibody specificity: Different anti-BIRC5 antibody clones may recognize distinct epitopes with variable accessibility across tissue types

• Isoform recognition: BIRC5 has multiple splice variants with differential expression patterns; antibodies may recognize specific isoforms

• Cancer heterogeneity: Compare expression patterns within and between cancer types:

  • NSCLC studies showed no significant elevation of anti-BIRC5 autoantibodies

  • Hepatocellular carcinoma studies identified elevated anti-BIRC5 autoantibodies

• Methodological differences: Compare:

  • Detection platforms (ELISA vs. protein microarray)

  • Sample processing protocols

  • Data normalization approaches

• Clinical context: Consider patient populations, disease stages, and treatment histories

A systematic review of methodologies and sample characteristics can help reconcile apparently contradictory findings and identify cancer-specific patterns of BIRC5 involvement.

What validation steps are necessary before implementing anti-BIRC5 autoantibody testing in clinical research studies?

Before implementing anti-BIRC5 autoantibody testing in clinical research, rigorous validation is essential:

• Analytical validation:

  • Precision: Intra-assay and inter-assay coefficients of variation

  • Accuracy: Recovery of spiked samples

  • Linearity: Serial dilution studies

  • Specificity: Cross-reactivity assessment

  • Sensitivity: Lower limit of detection and quantification

• Clinical validation:

  • Multi-center studies with diverse patient populations

  • Comparison with established biomarkers (e.g., AFP for hepatocellular carcinoma)

  • Stratification by disease stage, etiology, and comorbidities

• Standardization:

  • Reference materials development

  • Quality control implementation

  • Standard operating procedures documentation

• Statistical considerations:

  • Sample size calculations based on preliminary data

  • Appropriate statistical methods for biomarker evaluation

  • Establishment of reference ranges in relevant populations

Following these validation steps will ensure robust and reliable implementation of anti-BIRC5 autoantibody testing in clinical research contexts and facilitate comparison of results across studies .

What controls should be included when validating a new anti-BIRC5 antibody for research applications?

Proper validation of anti-BIRC5 antibodies requires a comprehensive set of controls:

• Positive tissue controls: Include tissues with confirmed BIRC5 expression

  • Myeloid leukemia cells

  • Mammary cancer tissues

  • Lung tissues

  • Cervix carcinoma samples

• Negative controls:

  • Isotype control antibodies

  • Tissues with minimal BIRC5 expression

  • Blocking peptide competition assays

• Method-specific controls:

  • For Western blot: Molecular weight markers, loading controls

  • For IHC: No primary antibody controls, isotype controls

  • For ELISA: Empty wells (no antigen), quality control samples

• Expression verification:

  • Complementary detection methods (e.g., mRNA expression)

  • Multiple antibody clones against different epitopes

  • siRNA knockdown validation in cell models

Including these comprehensive controls allows researchers to confidently attribute staining patterns to specific BIRC5 recognition rather than non-specific binding or technical artifacts .

How should researchers optimize anti-BIRC5 antibody concentrations for different experimental applications?

Optimization of anti-BIRC5 antibody concentrations requires methodical titration for each specific application:

• Western Blot optimization:

  • Begin with manufacturer's recommended dilution

  • Test 2-3 dilutions above and below recommended range

  • Optimize both primary and secondary antibody concentrations

  • Adjust exposure times to maintain signal linearity

• Immunohistochemistry optimization:

  • Perform antigen retrieval method comparison

  • Test multiple antibody concentrations on positive control tissues

  • Optimize incubation times and temperatures

  • Balance signal-to-noise ratio

• Flow Cytometry optimization:

  • Compare surface versus intracellular staining protocols

  • Titrate antibody to determine saturation point

  • Evaluate fixation and permeabilization protocols

  • Include fluorescence-minus-one (FMO) controls

• ELISA optimization:

  • Determine optimal coating concentration for BIRC5 antigen

  • Titrate primary antibody across broad concentration range

  • Optimize blocking conditions to minimize background

  • Evaluate detection system sensitivity

Systematic optimization for each application ensures maximal sensitivity and specificity while minimizing reagent consumption, providing researchers with reliable and reproducible results .

How can researchers distinguish between true BIRC5 expression and non-specific staining in immunohistochemistry?

Distinguishing specific from non-specific BIRC5 staining requires multiple technical and analytical approaches:

• Staining pattern analysis:

  • BIRC5 typically shows cytoplasmic localization

  • Nuclear staining may be observed in certain cancers

  • Compare observed patterns with literature-reported localizations

• Technical validations:

  • Parallel staining with multiple anti-BIRC5 antibody clones

  • Peptide competition assays to confirm specificity

  • Comparison with mRNA expression data from the same tissue

• Control tissues:

  • Include known positive and negative tissues in each staining run

  • Compare staining intensity across tissue types with expected expression levels

• Alternative fixation methods:

  • Compare formalin-fixed versus frozen tissue sections

  • Evaluate different antigen retrieval methods

When researchers observe BIRC5 staining in tissues like lung cytoplasm, they should reference literature confirming BIRC5 expression in these tissues (e.g., PubMed ID: 15489334) before concluding whether the staining represents true expression or artifact .

What factors contribute to variability in circulating anti-BIRC5 autoantibody levels in cancer patients?

Variability in circulating anti-BIRC5 autoantibody levels across cancer patients stems from multiple biological and technical factors:

• Tumor factors:

  • Cancer type and subtype (significant differences observed between NSCLC and hepatocellular carcinoma)

  • Disease stage and tumor burden

  • BIRC5 expression levels within tumor tissue

  • Tumor microenvironment and immune infiltration

• Patient factors:

  • Pre-existing autoimmune conditions

  • HBV infection status in liver cancer patients

  • Age and gender (matched in well-designed studies)

  • Prior cancer treatments and immune system status

• Methodological factors:

  • Assay platform differences (ELISA vs. protein microarray)

  • Sample handling and storage conditions

  • Normalization methods (SBI vs. SNR)

  • Inter-laboratory variability

• Study design factors:

  • Cohort selection criteria

  • Control group characteristics

  • Sample size limitations

Understanding these sources of variability is crucial for interpreting conflicting results between studies, such as the differing findings between anti-BIRC5 autoantibody levels in NSCLC versus hepatocellular carcinoma patients .